Definition and design of a new communication protocol and interfaces for data transmission in High Energy Physics experiments

High Energy Physics experiments have very similar architectures with respect to systems for acquisition of data from sensors and for control and management of the detector, and therefore similar requirements about data rate, trigger latency, robustness of critical data against transmission errors, radiation hardness and power dissipation and of hardware components and material budget. The use of common solutions that can be reused in different applicative contexts can reduce costs, risks and time needed for the development of new experiments. In particular, a research and development activity appeared as useful in the field of electrical links that are employed for data transmission to and from Front End circuits inside the detectors to move power-consuming optical converters away from the interaction point. Moving from these considerations, the FF-LYNX (Fast and Flexible links) project was started in January 2009 by a collaboration between INFN-PI (Italian National Institute for Nuclear Physics, division of Pisa) and the Department of Information Engineering (DII_IET) of the University of Pisa, with the aim of defining a new serial communication protocol for integrated distribution of TTC signals and Data Acquisition, satisfying the typical requirements of HEP applications and providing flexibility for its adaptation to different scenarios, and of its implementation in radiation-tolerant, low power interfaces. The work presented in this thesis constituted a phase of the FF-LYNX project working plan and was carried out at the Pisa division of INFN: in particular, it dealt with the definition of a first version of the FF-LYNX protocol and the design of hardware transmitter and receiver interfaces implementing it. In this thesis first of all the purposes of the project are presented and the methodology defined for the project work is outlined; then the FF-LYNX protocol (version 1) is described: the basic issues about trigger and data transmission that were considered in the definition of this version of the protocol are outlined, as well as the solutions that were adopted to address these issues, and the results of simulations in a high-level model of the link, intended to estimate various aspects of the protocol performance, are presented. Subsequently, the architecture that was defined for the interfaces implementing the FF-LYNX protocol version 1 is illustrated, and the VHDL models of the transmitter and receiver blocks that was created in the design phase of the FF-LYNX interfaces is described in detail also reporting results of simulations on a VHDL test bench for the complete transmitter-receiver system. Finally, an FPGA based emulator for the FF-LYNX transmitter-receiver system, foreseen as the final result for the FF-LYNX project first year of activity, is outlined in its functional architecture, the development board chosen for its implementation is briefly described, and the results of preliminary synthesis trials of the designed TX and RX blocks onto the target FPGA are reported

Synergistic interaction between trazodone and gabapentin in rodent models of neuropathic pain.

Neuropathic pain is a chronic debilitating condition caused by injury or disease of the nerves of the somatosensory system. Although several therapeutic approaches are recommended, none has emerged as an optimal treatment leaving a need for developing more effective therapies. Given the small number of approved drugs and their limited clinical efficacy, combining drugs with different mechanisms of action is frequently used to yield greater efficacy. We demonstrate that the combination of trazodone, a multifunctional drug for the treatment of major depressive disorders, and gabapentin, a GABA analogue approved for neuropathic pain relief, results in a synergistic antinociceptive effect in the mice writhing test. To explore the potential relevance of this finding in chronic neuropathic pain, pharmacodynamic interactions between low doses of trazodone (0.3 mg/kg) and gabapentin (3 mg/kg) were evaluated in the chronic constriction injury (CCI) rat model, measuring the effects of the two drugs both on evoked and spontaneous nociception and on general well being components. Two innate behaviors, burrowing and nest building, were used to assess these aspects. Besides exerting a significant antinociceptive effect on hyperalgesia and on spontaneous pain, combined inactive doses of trazodone and gabapentin restored in CCI rats innate behaviors that are strongly reduced or even abolished during persistent nociception, suggesting that the combination may have an impact also on pain components different from somatosensory perception. Our results support the development of a trazodone and gabapentin low doses combination product for optimal multimodal analgesia treatment

Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.

In this study, a drug discovery programme that sought to identify novel dual bacterial topoisomerase II inhibitors (NBTIs) led to the selection of six optimized compounds. In enzymatic assays, the molecules showed equivalent dual-targeting activity against the DNA gyrase and topoisomerase IV enzymes of Staphylococcus aureus and Escherichia coli. Consistently, the compounds demonstrated potent activity in susceptibility tests against various Gram-positive and Gram-negative reference species, including ciprofloxacin-resistant strains. The activity of the compounds against clinical multidrug-resistant isolates of S. aureus, Clostridium difficile, Acinetobacter baumannii, Neisseria gonorrhoeae, E. coli and vancomycin-resistant Enterococcus spp. was also confirmed. Two compounds (1 and 2) were tested in time-kill and post-antibiotic effect (PAE) assays. Compound 1 was bactericidal against all tested reference strains and showed higher activity than ciprofloxacin, and compound 2 showed a prolonged PAE, even against the ciprofloxacin-resistant S. aureus BAA-1720 strain. Spontaneous development of resistance to both compounds was selected for in S. aureus at frequencies comparable to those obtained for quinolones and other NBTIs. S. aureus BAA-1720 mutants resistant to compounds 1 and 2 had single point mutations in gyrA or gyrB outside of the quinolone resistance-determining region (QRDR), confirming the distinct site of action of these NBTIs compared to that of quinolones. Overall, the very good antibacterial activity of the compounds and their optimizable in vitro safety and physicochemical profile may have relevant implications for the development of new broad-spectrum antibiotics